{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:07:09Z","timestamp":1758931629876,"version":"3.44.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2020YFC2008900"],"award-info":[{"award-number":["2020YFC2008900"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-17641-7","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:45:43Z","timestamp":1758883543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cathepsin B in human peripheral blood lymphocytes as a peripheral biomarker for cardiac hypertrophy"],"prefix":"10.1038","volume":"15","author":[{"given":"Dandan","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuying","family":"Sui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianchun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"6","key":"17641_CR1","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1161\/HYPERTENSIONAHA.120.15487","volume":"76","author":"J Goto","year":"2020","unstructured":"Goto, J. et al. HECT (Homologous to the E6-AP carboxyl Terminus)-Type ubiquitin E3 ligase ITCH attenuates cardiac hypertrophy by suppressing the Wnt\/\u03b2-Catenin signaling pathway. Hypertension 76 (6), 1868\u20131878 (2020).","journal-title":"Hypertension"},{"issue":"9","key":"17641_CR2","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1097\/HJH.0000000000003774","volume":"42","author":"DB \u0110or\u0111evi\u0107","year":"2024","unstructured":"\u0110or\u0111evi\u0107, D. B., Kora\u010devi\u0107, G. P., \u0110or\u0111evi\u0107, A. D. & Lovi\u0107, D. B. Hypertension and left ventricular hypertrophy. J. Hypertens. 42 (9), 1505\u20131515 (2024).","journal-title":"J. Hypertens."},{"issue":"16","key":"17641_CR3","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.115.013894","volume":"131","author":"GG Schiattarella","year":"2015","unstructured":"Schiattarella, G. G. & Hill, J. A. Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload. Circulation 131 (16), 1435\u20131447 (2015).","journal-title":"Circulation"},{"issue":"1","key":"17641_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2012.10.002","volume":"1","author":"E Braunwald","year":"2013","unstructured":"Braunwald, E. Heart failure. JACC Heart Fail. 1 (1), 1\u201320 (2013).","journal-title":"JACC Heart Fail."},{"issue":"3","key":"17641_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cmet.2020.12.003","volume":"33","author":"AA Cluntun","year":"2021","unstructured":"Cluntun, A. A. et al. The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure. Cell Metabol. 33 (3), 629\u2013648e10 (2021).","journal-title":"Cell Metabol."},{"issue":"2","key":"17641_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1139\/cjpp-2019-0566","volume":"98","author":"CJ Oldfield","year":"2020","unstructured":"Oldfield, C. J., Duhamel, T. A. & Dhalla, N. S. Mechanisms for the transition from physiological to pathological cardiac hypertrophy. Can. J. Physiol. Pharmacol. 98 (2), 74\u201384 (2020).","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"1","key":"17641_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bbapap.2011.10.002","volume":"1824","author":"V Turk","year":"2012","unstructured":"Turk, V. et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim. Biophys. Acta. 1824 (1), 68\u201388 (2012).","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"17641_CR8","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1002\/j.1460-2075.1991.tb07771.x","volume":"10","author":"D Musil","year":"1991","unstructured":"Musil, D. et al. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J. 10 (9), 2321\u20132330 (1991).","journal-title":"EMBO J."},{"issue":"3","key":"17641_CR9","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1161\/HYPERTENSIONAHA.121.17177","volume":"78","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Piezo1-Mediated mechanotransduction promotes cardiac hypertrophy by impairing calcium homeostasis to activate calpain\/calcineurin signaling. Hypertens. (Dallas Tex. : 1979). 78 (3), 647\u2013660 (2021).","journal-title":"Hypertens. (Dallas Tex. : 1979)"},{"issue":"8","key":"17641_CR10","doi-asserted-by":"publisher","first-page":"140428","DOI":"10.1016\/j.bbapap.2020.140428","volume":"1868","author":"V Hook","year":"2020","unstructured":"Hook, V. et al. Cathepsin B in neurodegeneration of alzheimer\u2019s disease, traumatic brain injury, and related brain disorders. Biochimica et biophysica acta. Proteins Proteom. 1868 (8), 140428 (2020).","journal-title":"Proteins Proteom."},{"issue":"21","key":"17641_CR11","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1101\/gad.250647.114","volume":"28","author":"L Sevenich","year":"2014","unstructured":"Sevenich, L. & Joyce, J. A. Pericellular proteolysis in cancer. Genes Dev. 28 (21), 2331\u20132347 (2014).","journal-title":"Genes Dev."},{"issue":"4","key":"17641_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jacbts.2018.05.004","volume":"3","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Targeting Calpain for heart failure therapy: implications from multiple murine models. JACC Basic. Translational Sci. 3 (4), 503\u2013517 (2018).","journal-title":"JACC Basic. Translational Sci."},{"issue":"6","key":"17641_CR13","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1161\/CIRCRESAHA.107.160077","volume":"102","author":"E Letavernier","year":"2008","unstructured":"Letavernier, E. et al. Targeting the calpain\/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension. Circul. Res. 102 (6), 720\u2013728 (2008).","journal-title":"Circul. Res."},{"key":"17641_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.freeradbiomed.2022.02.027","volume":"182","author":"F Wang","year":"2022","unstructured":"Wang, F. et al. Silica nanoparticles induce pyroptosis and cardiac hypertrophy via ROS\/NLRP3\/Caspase-1 pathway. Free Radic. Biol. Med. 182, 171\u2013181 (2022).","journal-title":"Free Radic. Biol. Med."},{"issue":"12","key":"17641_CR15","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1096\/fj.06-7924com","volume":"21","author":"SP Lutgens","year":"2007","unstructured":"Lutgens, S. P., Cleutjens, K. B., Daemen, M. J. & Heeneman, S. Cathepsin cysteine proteases in cardiovascular disease. FASEB Journal: Official Publication Federation Am. Soc. Experimental Biology. 21 (12), 3029\u20133041 (2007).","journal-title":"FASEB Journal: Official Publication Federation Am. Soc. Experimental Biology"},{"key":"17641_CR16","doi-asserted-by":"publisher","first-page":"109770","DOI":"10.1016\/j.cellsig.2020.109770","volume":"76","author":"D O\u2019Toole","year":"2020","unstructured":"O\u2019Toole, D. et al. Signalling pathways linking cysteine cathepsins to adverse cardiac remodelling. Cell. Signal. 76, 109770 (2020).","journal-title":"Cell. Signal."},{"issue":"9","key":"17641_CR17","doi-asserted-by":"publisher","first-page":"H1143","DOI":"10.1152\/ajpheart.00601.2014","volume":"308","author":"QQ Wu","year":"2015","unstructured":"Wu, Q. Q. et al. Cathepsin B deficiency attenuates cardiac remodeling in response to pressure overload via TNF-\u03b1\/ASK1\/JNK pathway. Am. J. Physiol. Heart Circ. Physiol. 308 (9), H1143\u2013H1154 (2015).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"5","key":"17641_CR18","doi-asserted-by":"publisher","first-page":"7873","DOI":"10.3892\/mmr.2017.7551","volume":"16","author":"A Liu","year":"2017","unstructured":"Liu, A., Gao, X., Zhang, Q. & Cui, L. Cathepsin B Inhibition attenuates cardiac dysfunction and remodeling following myocardial infarction by inhibiting the NLRP3 pathway. Mol. Med. Rep. 16 (5), 7873 (2017).","journal-title":"Mol. Med. Rep."},{"issue":"12","key":"17641_CR19","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1161\/CIRCULATIONAHA.111.066712","volume":"125","author":"XW Cheng","year":"2012","unstructured":"Cheng, X. W. et al. Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation 125 (12), 1551\u20131562 (2012).","journal-title":"Circulation"},{"issue":"3","key":"17641_CR20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ejheart.2005.09.004","volume":"8","author":"J Ge","year":"2006","unstructured":"Ge, J. et al. Enhanced myocardial cathepsin B expression in patients with dilated cardiomyopathy. Eur. J. Heart Fail. 8 (3), 284\u2013289 (2006).","journal-title":"Eur. J. Heart Fail."},{"key":"17641_CR21","unstructured":"Li, C. et al. Relationship between calcineurin - nuclear factor of activated T cells pathway and atrial fibrillation in patients with valvular heart disease. J. Shandong Univ. (Med Edition)\u00a08, 47\u201351. (2014)."},{"key":"17641_CR22","first-page":"113","volume":"02","author":"MM Wang","year":"2008","unstructured":"Wang, M. M., Zhao, Y., Liu, W., Zhang, J. & Wang, J. C. A preliminary report on the correlation between calcineurin Mrna levels in peripheral blood lymphocytes and myocardial tissue in patients with heart failure. Chin. J. Circulation. 02, 113\u2013116 (2008).","journal-title":"Chin. J. Circulation"},{"issue":"9","key":"17641_CR23","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","volume":"89","author":"YK Tham","year":"2015","unstructured":"Tham, Y. K., Bernardo, B. C., Ooi, J. Y., Weeks, K. L. & McMullen, J. R. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch. Toxicol. 89 (9), 1401\u20131438 (2015).","journal-title":"Arch. Toxicol."},{"issue":"2","key":"17641_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semcancer.2004.08.001","volume":"15","author":"BF Sloane","year":"2005","unstructured":"Sloane, B. F. et al. Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. Semin Cancer Biol. 15 (2), 149\u2013157 (2005).","journal-title":"Semin Cancer Biol."},{"issue":"16","key":"17641_CR25","doi-asserted-by":"publisher","first-page":"e2300099120","DOI":"10.1073\/pnas.2300099120","volume":"120","author":"MY Chou","year":"2023","unstructured":"Chou, M. Y., Liu, D., An, J., Xu, Y. & Cyster, J. G. B cell peripheral tolerance is promoted by cathepsin B protease. Proc. Natl. Acad. Sci. U S A. 120 (16), e2300099120 (2023).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"17641_CR26","doi-asserted-by":"publisher","first-page":"1053754","DOI":"10.3389\/fimmu.2022.1053754","volume":"13","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Cathepsin B promotes sepsis-induced acute kidney injury through activating mitochondrial apoptosis pathway. Front. Immunol. 13, 1053754 (2023).","journal-title":"Front. Immunol."},{"issue":"12","key":"17641_CR27","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1080\/15548627.2016.1239679","volume":"12","author":"SM Man","year":"2016","unstructured":"Man, S. M. & Kanneganti, T. D. Regulation of lysosomal dynamics and autophagy by cathepsin b\/cathepsin B. Autophagy 12 (12), 2504\u20132505 (2016).","journal-title":"Autophagy"},{"key":"17641_CR28","doi-asserted-by":"publisher","first-page":"107496","DOI":"10.1016\/j.intimp.2021.107496","volume":"94","author":"J Wang","year":"2021","unstructured":"Wang, J. et al. Cathepsin B aggravates acute pancreatitis by activating the NLRP3 inflammasome and promoting the caspase-1-induced pyroptosis. Int. Immunopharmacol. 94, 107496 (2021).","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"17641_CR29","doi-asserted-by":"publisher","first-page":"e1006872","DOI":"10.1371\/journal.ppat.1006872","volume":"14","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Cathepsin B aggravates coxsackievirus B3-induced myocarditis through activating the inflammasome and promoting pyroptosis. PLoS Pathog. 14 (1), e1006872 (2018).","journal-title":"PLoS Pathog"},{"issue":"17","key":"17641_CR30","doi-asserted-by":"publisher","first-page":"e70064","DOI":"10.1111\/jcmm.70064","volume":"28","author":"Z Cai","year":"2024","unstructured":"Cai, Z., Xu, S. & Liu, C. Cathepsin B in cardiovascular disease: underlying mechanisms and therapeutic strategies. J. Cell. Mol. Med. 28 (17), e70064 (2024).","journal-title":"J. Cell. Mol. Med."},{"key":"17641_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.arr.2016.04.010","volume":"32","author":"V Stoka","year":"2016","unstructured":"Stoka, V., Turk, V. & Turk, B. Lysosomal cathepsins and their regulation in aging and neurodegeneration. Ageing Res. Rev. 32, 22\u201337 (2016).","journal-title":"Ageing Res. Rev."},{"issue":"17","key":"17641_CR32","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1093\/emboj\/20.17.4629","volume":"20","author":"V Turk","year":"2001","unstructured":"Turk, V., Turk, B. & Turk, D. Lysosomal cysteine proteases: facts and opportunities. EMBO J. 20 (17), 4629\u20134633 (2001).","journal-title":"EMBO J."},{"key":"17641_CR33","doi-asserted-by":"publisher","first-page":"173420","DOI":"10.1016\/j.ejphar.2020.173420","volume":"888","author":"S Riaz","year":"2020","unstructured":"Riaz, S. et al. Anti-hypertrophic effect of Na+\/H\u2009+\u2009exchanger-1 Inhibition is mediated by reduced cathepsin B. Eur. J. Pharmacol. 888, 173420 (2020).","journal-title":"Eur. J. Pharmacol."},{"key":"17641_CR34","first-page":"56","volume":"22","author":"A Diwan","year":"2007","unstructured":"Diwan, A. & Dorn, G. W. 2 Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. Physiol. (Bethesda). 22, 56\u201364 (2007).","journal-title":"Physiol. (Bethesda)"},{"issue":"1","key":"17641_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/cvr\/cvae241","volume":"121","author":"C Lan","year":"2025","unstructured":"Lan, C. et al. SerpinB1 targeting safeguards against pathological cardiac hypertrophy and remodelling by suppressing cardiomyocyte pyroptosis and inflammation initiation. Cardiovasc. Res. 121 (1), 113\u2013127 (2025).","journal-title":"Cardiovasc. Res."},{"issue":"4","key":"17641_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41419-023-05786-0","volume":"14","author":"Z Xie","year":"2023","unstructured":"Xie, Z. et al. Cathepsin B in programmed cell death machinery: mechanisms of execution and regulatory pathways. Cell. Death Dis. 14 (4), 255 (2023).","journal-title":"Cell. Death Dis."},{"key":"17641_CR37","doi-asserted-by":"publisher","first-page":"289734","DOI":"10.1155\/2015\/289734","volume":"2015","author":"L Musante","year":"2015","unstructured":"Musante, L. et al. Proteases and protease inhibitors of urinary extracellular vesicles in diabetic nephropathy. J. Diabetes Res. 2015, 289734 (2015).","journal-title":"J. Diabetes Res."},{"key":"17641_CR38","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.archger.2016.03.015","volume":"65","author":"N Wang","year":"2016","unstructured":"Wang, N. et al. The association of serum cathepsin B concentration with age-related cardiovascular-renal subclinical state in a healthy Chinese population. Arch. Gerontol. Geriatr. 65, 146\u2013155 (2016).","journal-title":"Arch. Gerontol. Geriatr."},{"issue":"1","key":"17641_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.amjms.2015.10.004","volume":"351","author":"SC Chen","year":"2016","unstructured":"Chen, S. C. et al. Body mass index, left ventricular mass index and cardiovascular events in chronic kidney disease. Am. J. Med. Sci. 351 (1), 91\u201396 (2016).","journal-title":"Am. J. Med. Sci."},{"issue":"12","key":"17641_CR40","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia, G. et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA). J. Hypertens. 41 (12), 1874\u20132071 (2023).","journal-title":"J. Hypertens."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17641-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17641-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17641-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:45:45Z","timestamp":1758883545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17641-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17641"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17641-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong First Medical University. Written informed consent was also obtained from the patient for the acquisition of blood and left atrial appendage specimens.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"32980"}}